COVID vaccine in lung cancer COVID-19 Vaccines Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma Lung Neoplasms
Conditions
Interventions
Patients with lung cancer with any stages, treatments and responses after treatment that include complete remission disease. Patients have received chemotherapy within 4 weeks for anti-cancer treatmen
Prevention,Prevention
Patients with lung cancer (chemotherapy),Patients with lung cancer (no chemotherapy)
Sponsors
Faculty of Medicine, Chiang Mai University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. age 18 years or above 2. Has an appointment to receive COVID-19 vaccine 3. Confirmed diagnosis of lung cancer by pathology or cytology 4. Life expectancy is more than 6 months at the time receiving first
Exclusion criteria
Exclusion criteria: 1. Previously diagnosed COVID-19 in the past 90 days 2. High-risk epidemiology history within 14 days before enrolment e.g. close contact with index cases or visiting/ living in outbreak area 3. Receive only one dose of COVID-19 vaccine 4. Receive blood products, blood components, or immunoglobulin within the past 90 days 5. Receive live attenuated vaccine in the past 28 days 6. Receive inactivated or subunit vaccines in the past 14 days 7. Women in lactation, pregnancy, or planned pregnancy during the study period 8. Known allergy to any vaccine component 9. Has signs and symptoms of active skin infection at injection site 10.Known history of HIV infection 11. Has uncontrolled medical illness that include cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seroconversion rate of neutralizing antibody 28 days after second dose of vaccine percent inhibition of neutralizing antibody | — |
Secondary
| Measure | Time frame |
|---|---|
| Seroconversion rate of neutralizing antibody 6 months after second dose of vaccine percent inhibition of neutralizing antibody,Cell mediated immunity 28 days after second dose of vaccine intracellular cytokine staining for IFN-gamma, TNF-alpha, IL-4, IL-10 in CD3,CD4 and CD8 positive cell,safety outcome 28 days and 6 months after second dose of vaccine patients reported outcome using questionnaire interview about adverse events | — |
Countries
Thailand
Contacts
Public ContactBusyamas Chewaskulyong
Faculty of Medicine, Chiang Mai University
Outcome results
None listed